Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1988 in Clinical High Risk for Psychosis
NCT07226895Phase 2Recruiting
- Sponsor
- Monument Therapeutics
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT1988 in Clinical high risk for psychosis (CHR), sponsored by Monument Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
MT1988
03
Conditions
Clinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on NCT07226895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226895.